Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Actome GmbH manages a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action. This action is assigned to 1 distinct art unit, reflecting a concentrated technical scope for the company's current intellectual property efforts.
The prosecution involves 1 distinct examiner, FERNANDO NMN IVICH. This examiner is the busiest examiner for the company, with 1 busiest examiner pending action. Because there is only 1 pending office action, the entire prosecution workload is handled by the 1 distinct examiner. Practitioners should note that the 1 busiest examiner pending action accounts for the total volume of current activity at the patent office. The presence of the 1 distinct art unit indicates that the company's filings are not spread across different technical divisions. This streamlined structure means that the 1 pending office action is the sole focus of the company's current patent office interactions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| IVICH, FERNANDO NMN | 1 | 52.4% | +72.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17597023 | METHOD AND KIT FOR MEASURING OF ANALYTES IN BI-COMPONENT SYSTEMS AND USES THEREOF | IVICH, FERNANDO NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17597023 | METHOD AND KIT FOR MEASURING OF ANALYTES IN BI-COMPONENT SYSTEMS AND USES THEREOF | IVICH, FERNANDO NMN | — |
| Art Unit | Apps |
|---|---|
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17597023 | METHOD AND KIT FOR MEASURING OF ANALYTES IN BI-COMPONENT SYSTEMS AND USES THEREOF | IVICH, FERNANDO NMN | 1678 | §101§112 | Final Rejection | — | Pending | Dec 22, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialActome GmbH has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Fernando Nmn Ivich has the most, with 1 of Actome GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
